Novartis AG
NVS
$112.43
$0.54630.49%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 50.32B | 48.59B | 47.55B | 46.47B | 45.44B |
| Total Other Revenue | 1.41B | 1.35B | 1.31B | 1.26B | 1.22B |
| Total Revenue | 51.72B | 49.94B | 48.86B | 47.73B | 46.66B |
| Cost of Revenue | 12.82B | 12.07B | 11.95B | 12.12B | 12.02B |
| Gross Profit | 38.91B | 37.87B | 36.91B | 35.61B | 34.64B |
| SG&A Expenses | 12.56B | 12.48B | 12.44B | 12.44B | 12.49B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 335.00M | -255.00M | 30.00M | 132.00M | 417.00M |
| Total Operating Expenses | 35.22B | 31.44B | 33.10B | 33.36B | 33.94B |
| Operating Income | 16.50B | 18.50B | 15.76B | 14.37B | 12.72B |
| Income Before Tax | 13.64B | 12.73B | 10.90B | 9.73B | 9.12B |
| Income Tax Expenses | 1.70B | 975.00M | 814.00M | 622.00M | 551.00M |
| Earnings from Continuing Operations | 11.94K | 11.76K | 10.09K | 9.11K | 8.57K |
| Earnings from Discontinued Operations | -- | 5.84B | 6.09B | 6.14B | 6.28B |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.00M | 4.00M | -2.00M | -3.00M | -4.00M |
| Net Income | 11.94B | 17.60B | 16.18B | 15.25B | 14.85B |
| EBIT | 16.50B | 18.50B | 15.76B | 14.37B | 12.72B |
| EBITDA | 19.84B | 22.83B | 20.24B | 18.99B | 17.57B |
| EPS Basic | 5.92 | 8.63 | 7.90 | 7.42 | 7.19 |
| Normalized Basic EPS | 4.93 | 5.51 | 4.64 | 4.21 | 3.71 |
| EPS Diluted | 5.88 | 8.58 | 7.86 | 7.38 | 7.15 |
| Normalized Diluted EPS | 4.90 | 5.47 | 4.61 | 4.18 | 3.68 |
| Average Basic Shares Outstanding | 8.08B | 8.14B | 8.19B | 8.24B | 8.31B |
| Average Diluted Shares Outstanding | 8.13B | 8.19B | 8.24B | 8.29B | 8.36B |
| Dividend Per Share | 3.86 | 3.92 | 3.92 | 3.92 | 3.92 |
| Payout Ratio | 63.85% | 43.31% | 47.13% | 34.16% | 48.86% |
